List of Publicly Traded Small-Cap Healthcare Companies
Comprehensive directory and market analysis of high-growth small-cap healthcare stocks, from innovative diagnostics to speculative biotech pioneers.
Navigating the List of Publicly Traded Small-Cap Healthcare Companies offers investors a gateway to high-growth opportunities in diagnostics, telehealth, and clinical-stage biotechnology. As of early 2026, the segment has significantly outperformed broader indices, driven by breakthrough trial data and a resurgence in healthcare M&A activity. To effectively evaluate these volatile entities, many utilize our compare small-cap healthcare tool to benchmark revenue acceleration against peer groups. This directory tracks the primary innovators currently defining the all sectors framework, focusing on companies with market capitalizations typically between $300 million and $2 billion. For a broader view of the industry, you can also explore our full healthcare list to compare these growth names with established market leaders.
Key Takeaways
Small-cap healthcare is currently outperforming the Russell 2000, with top momentum names like Galectin (GALT) seeing returns over 200% YTD.
Leaders in organ transplant tech and diagnostic imaging, such as TransMedics (TMDX), are successfully scaling toward large-cap status in 2026.
Biotech returns remain heavily dependent on clinical trial milestones and FDA catalysts, which can drive triple-digit swings in share price.
With legacy names being acquired at a rapid pace, the current small-cap roster is a primary focus for larger entities looking to bolster their pipelines. Research small-cap med devices for potential acquisition candidates.
Top List of Publicly Traded Small-Cap Healthcare Companies by Market Cap (2026)
The following table identifies the 2026 market leaders within the small-cap healthcare space, focusing on growth metrics and YTD performance.
| Rank | Ticker | Company | Industry | Market Cap | YTD % | P/E Ratio | Revenue Growth |
|---|---|---|---|---|---|---|---|
| 1 | TMDX | TransMedics Group | Medical Tech | $3.5B | +42% | N/A | +150% |
| 2 | LNTH | Lantheus Holdings | Diagnostics | $1.8B | +18% | 14.2x | +35% |
| 3 | CTMX | CytomX Therapeutics | Biotech | $376M | +137% | N/A | N/A |
| 4 | GALT | Galectin Pharma | Biotech | $263M | +211% | N/A | N/A |
| 5 | TOI | Oncology Institute | Services | $410M | +65% | N/A | +48% |
| 6 | MEDP | Medpace Holdings | CRO | $1.9B | +12% | 22.1x | +24% |
| 7 | ZEPP | Zepp Health | Health Tech | $320M | +5% | 8.4x | +15% |
| 8 | QDEL | QuidelOrtho | Diagnostics | $2.0B | -4% | 11.5x | +5% |
List of Publicly Traded Small-Cap Healthcare Companies — Complete Company List
List of Publicly Traded Small-Cap Healthcare Companies Listed on U.S. Exchanges
Small-Cap Healthcare Resources
Diagnostics
- Abaxis, Inc. (ABAX) (Point-of-care blood analyzers for humans and animals)
- Accelerate Diagnostics, Inc. (AXDX) (Tests for infectious pathogens)
- Heska Corporation (HSKA) (Veterinary diagnostic and specialty veterinary products)
- Lantheus Holdings, Inc. (LNTH) (IPO in June 2015: Diagnostic medical imaging agents; heart failure, coronary artery disease, peripheral vascular disease, strokes)
- Meridian Bioscience Inc. (VIVO) (Tests for respiratory infections, parasitology, foodborne diseases)
- OraSure Technologies, Inc. (OSUR) (Point-of-care diagnostics and collection devices)
- Oxford Immunotec Global Plc. (OXFD) (United Kingdom: immunology diagnostic company)
- Quanterix Corporation (QTRX) (IPO December 7, 2017; digital immunoassay platform)
- Quidel Corporation (QDEL) (Tests for infectious diseases, gastrointestinal diseases, women’s health)
- SurModics, Inc. (SRDX) (Two core businesses: in vitro diagnostics and medical device coatings)
Diagnostic Imaging Centers
- RadNet, Inc. (RDNT) (Fixed-site diagnostic imaging services through it’s over 250 outpatient imaging centers)
Healthcare Research Services
- Medpace Holdings, Inc. (MEDP) (IPO August 11, 2016: clinical contract research organization)
- National Research Corporation (NRC) (Healthcare research and quality improvement services for health care providers)
Healthcare Services
- AMN Healthcare Services Inc. (AMN) (Healthcare staffing and workforce services)
- CorVel Corp. (CRVL) (Risk and healthcare management solutions)
- CRH Medical Corporation (CRHM) (Products and services for physicians)
- Cross Country Healthcare, Inc. (CCRN) (Healthcare staffing)
- Evolent Health, Inc. (EVH) (IPO in June 2015: Integrated healthcare payment and delivery platform)
- HMS Holdings Corp (HMSY) (Provides services to the healthcare insurance benefit industry)
- Magellan Health, Inc. (MGLN) (Specialty health care manager)
- NantHealth, Inc. (NH) (IPO June 2, 2016: personalized healthcare company; healthcare data solutions)
- Premier, Inc. (PINC) (Member-owned alliance of hospitals and healthcare providers)
- R1 RCM Inc. (RCM) (Revenue cycle management services)
Molecular Diagnostics
- GenMark Diagnostics, Inc. (GNMK) (Cystic fibrosis, respiratory viral)
- Genomic Health, Inc. (GHDX) (Molecular oncology)
- Invitae Corporation (NVTA) (Genetic diagnostics for hereditary disorders)
- Myriad Genetics, Inc. (MYGN) (Hereditary cancer, nephrology, autoimmune diseases, diabetes, neuropsychiatry)
- Natera Inc. (NTRA) (IPO in July 2015: Genetic testing and diagnostics company)
Specialty Pharmacy
- Diplomat Pharmacy, Inc. (DPLO) (Independent specialty pharmacy)
Telehealth
- Teladoc Inc. (TDOC) (IPO in July 2015: Telehealth provider)
Risks & Considerations
Clinical Trial and FDA Binary Risk
For small-cap biotech names, a single failed Phase 3 trial or an FDA "Complete Response Letter" can result in immediate stock devaluations exceeding 70%.
Reimbursement and Payer Barriers
Small-cap innovators often face significant hurdles in securing insurance coverage for new therapies or diagnostics, which can delay revenue and extend cash burn.
Dilution and Capital Needs
Many companies in this segment are not yet profitable. Secondary offerings and debt financing are common, which can dilute existing shareholders to fund R&D operations.
Market Liquidity and Volatility
Lower trading volumes in the small-cap segment can lead to extreme price swings on minimal news, making it difficult to execute large positions without impacting the market price.